Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Clinical significance of NUCB2 mRNA expression in prostate cancer.

Zhang H, Qi C, Li L, Luo F, Xu Y.

J Exp Clin Cancer Res. 2013 Aug 16;32(1):56. doi: 10.1186/1756-9966-32-56.

2.

Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer.

Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, Xu Y.

J Exp Clin Cancer Res. 2013 Oct 16;32:77. doi: 10.1186/1756-9966-32-77.

3.

High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer.

Zhang H, Qi C, Wang A, Li L, Xu Y.

Tumour Biol. 2014 Mar;35(3):2025-8. doi: 10.1007/s13277-013-1268-z. Epub 2013 Oct 4.

PMID:
24092574
4.

Nucleobindin 2 expression is an independent prognostic factor for clear cell renal cell carcinoma.

Qi C, Ma H, Zhang HT, Gao JD, Xu Y.

Histopathology. 2015 Apr;66(5):650-7. doi: 10.1111/his.12587. Epub 2014 Dec 22.

PMID:
25322808
5.

Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.

Sun X, Liu Z, Yang Z, Xiao L, Wang F, He Y, Su P, Wang J, Jing B.

Diagn Pathol. 2013 Dec 18;8:208. doi: 10.1186/1746-1596-8-208.

6.

Nucleobindin 2 in human breast carcinoma as a potent prognostic factor.

Suzuki S, Takagi K, Miki Y, Onodera Y, Akahira J, Ebata A, Ishida T, Watanabe M, Sasano H, Suzuki T.

Cancer Sci. 2012 Jan;103(1):136-43. doi: 10.1111/j.1349-7006.2011.02119.x. Epub 2011 Nov 17.

7.

Expression of SOCSs in human prostate cancer and their association in prognosis.

Zhu JG, Dai QS, Han ZD, He HC, Mo RJ, Chen G, Chen YF, Wu YD, Yang SB, Jiang FN, Chen WH, Sun ZL, Zhong WD.

Mol Cell Biochem. 2013 Sep;381(1-2):51-9. doi: 10.1007/s11010-013-1687-6. Epub 2013 May 11.

PMID:
23666742
8.
9.

Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer.

Zhang H, Wei Q, Liu R, Qi S, Liang P, Qi C, Wang A, Sheng B, Li L, Xu Y.

PLoS One. 2014 Mar 20;9(3):e91069. doi: 10.1371/journal.pone.0091069. eCollection 2014.

10.

Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.

Debiais-Delpech C, Godet J, Pedretti N, Bernard FX, Irani J, Cathelineau X, Cussenot O, Fromont G.

Urol Oncol. 2014 May;32(4):426-32. doi: 10.1016/j.urolonc.2013.09.006. Epub 2013 Dec 12.

PMID:
24332637
11.

Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.

Li T, Gui Y, Yuan T, Liao G, Bian C, Jiang Q, Huang S, Liu B, Wu D.

BJU Int. 2012 Dec;110(11 Pt C):E1125-30. doi: 10.1111/j.1464-410X.2012.11277.x. Epub 2012 Jun 6.

12.

L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.

Koutalellis G, Stravodimos K, Avgeris M, Mavridis K, Scorilas A, Lazaris A, Constantinides C.

BJU Int. 2012 Sep;110(6 Pt B):E267-73. doi: 10.1111/j.1464-410X.2012.11152.x. Epub 2012 May 9.

14.

Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.

Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, Schicktanz H, Loening SA, Kristiansen G, Jung K.

Eur Urol. 2007 May;51(5):1259-66. Epub 2006 Jun 14.

PMID:
16806661
15.

Detection of pelvic lymph node micrometastasis by real-time reverse transcriptase polymerase chain reaction in prostate cancer patients after hormonal therapy.

Liu DY, Xia WM, Tang Q, Wang J, Wang MW, Wang Y, Wang SJ, Ye YF, Zhou WL, Shao Y.

J Cancer Res Clin Oncol. 2014 Feb;140(2):235-41. doi: 10.1007/s00432-013-1558-2. Epub 2013 Dec 1.

PMID:
24292502
16.

Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.

Sun X, Yang Z, Zhang Y, He J, Wang F, Su P, Han J, Song Z, Fei Y.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8394-401. eCollection 2015.

17.

Expression of RABEX-5 and its clinical significance in prostate cancer.

Zhang H, Cheng S, Wang A, Ma H, Yao B, Qi C, Liu R, Qi S, Xu Y.

J Exp Clin Cancer Res. 2014 Apr 9;33:31. doi: 10.1186/1756-9966-33-31.

18.

Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.

Zhuo YJ, Xi M, Wan YP, Hua W, Liu YL, Wan S, Zhou YL, Luo HW, Wu SL, Zhong WD, Wu CL.

Int J Mol Med. 2015 Apr;35(4):966-72. doi: 10.3892/ijmm.2015.2086. Epub 2015 Jan 30.

PMID:
25647485
19.

Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics.

March-Villalba JA, Martínez-Jabaloyas JM, Herrero MJ, Santamaria J, Aliño SF, Dasí F.

PLoS One. 2012;7(8):e43470. doi: 10.1371/journal.pone.0043470. Epub 2012 Aug 20.

20.

MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.

Ling XH, Han ZD, Xia D, He HC, Jiang FN, Lin ZY, Fu X, Deng YH, Dai QS, Cai C, Chen JH, Liang YX, Zhong WD, Wu CL.

Mol Biol Rep. 2014 May;41(5):2779-88. doi: 10.1007/s11033-014-3132-7. Epub 2014 Jan 23.

PMID:
24452717

Supplemental Content

Support Center